213 related articles for article (PubMed ID: 29168171)
1. The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.
De Santo C; Booth S; Vardon A; Cousins A; Tubb V; Perry T; Noyvert B; Beggs A; Ng M; Halsey C; Kearns P; Cheng P; Mussai F
Int J Cancer; 2018 Apr; 142(7):1490-1502. PubMed ID: 29168171
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer.
Xu S; Lam SK; Cheng PN; Ho JC
Cancer Sci; 2018 Nov; 109(11):3471-3482. PubMed ID: 30155941
[TBL] [Abstract][Full Text] [Related]
3. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
4. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.
Mussai F; Egan S; Higginbotham-Jones J; Perry T; Beggs A; Odintsova E; Loke J; Pratt G; U KP; Lo A; Ng M; Kearns P; Cheng P; De Santo C
Blood; 2015 Apr; 125(15):2386-96. PubMed ID: 25710880
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Chan SL; Cheng PNM; Liu AM; Chan LL; Li L; Chu CM; Chong CCN; Lau YM; Yeo W; Ng KKC; Yu SCH; Mok TSK; Chan AWH
Invest New Drugs; 2021 Oct; 39(5):1375-1382. PubMed ID: 33856599
[TBL] [Abstract][Full Text] [Related]
6. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
7. Pegylated arginase I: a potential therapeutic approach in T-ALL.
Hernandez CP; Morrow K; Lopez-Barcons LA; Zabaleta J; Sierra R; Velasco C; Cole J; Rodriguez PC
Blood; 2010 Jun; 115(25):5214-21. PubMed ID: 20407034
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
9. Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment.
Kwong-Lam F; Chi-Fung CG
Exp Hematol Oncol; 2013 Apr; 2(1):11. PubMed ID: 23574711
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Recombinant Human Arginase 1 Induces Autophagy and Apoptosis via the ROS-Activated AKT/mTOR Pathway in Bladder Cancer Cells.
Zhao Z; Zhang P; Li W; Wang D; Ke C; Liu Y; Ho JC; Cheng PN; Xu S
Oxid Med Cell Longev; 2021; 2021():5510663. PubMed ID: 33791071
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.
Alexandrou C; Al-Aqbi SS; Higgins JA; Boyle W; Karmokar A; Andreadi C; Luo JL; Moore DA; Viskaduraki M; Blades M; Murray GI; Howells LM; Thomas A; Brown K; Cheng PN; Rufini A
Sci Rep; 2018 Aug; 8(1):12096. PubMed ID: 30108309
[TBL] [Abstract][Full Text] [Related]
12. Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.
De Santo C; Cheng P; Beggs A; Egan S; Bessudo A; Mussai F
J Hematol Oncol; 2018 May; 11(1):68. PubMed ID: 29776373
[TBL] [Abstract][Full Text] [Related]
13. Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1.
Agnello G; Alters SE; Rowlinson SW
Transl Res; 2020 Mar; 217():11-22. PubMed ID: 31954097
[TBL] [Abstract][Full Text] [Related]
14. Human Recombinant Arginase I [HuArgI (Co)-PEG5000]-Induced Arginine Depletion Inhibits Colorectal Cancer Cell Migration and Invasion.
Al-Koussa H; Al-Haddad M; Abi-Habib R; El-Sibai M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795337
[TBL] [Abstract][Full Text] [Related]
15. Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors.
Cheng PNM; Liu AM; Bessudo A; Mussai F
Invest New Drugs; 2021 Dec; 39(6):1633-1640. PubMed ID: 34287772
[TBL] [Abstract][Full Text] [Related]
16. Effects of the combined arginase and canavanine treatment on leukemic cells in vitro and in vivo.
Vovk OI; Chen OI; Igumentseva NI; Senchuk OY; Barska ML; Sybirna NO; Stasyk OV
Ukr Biochem J; 2016; 88(2):45-55. PubMed ID: 29227602
[TBL] [Abstract][Full Text] [Related]
17. Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma.
Lam SK; Yan S; Xu S; U KP; Cheng PN; Ho JC
Oncogenesis; 2019 Feb; 8(3):18. PubMed ID: 30808864
[TBL] [Abstract][Full Text] [Related]
18. Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1.
Glazer ES; Kaluarachchi WD; Massey KL; Zhu C; Curley SA
Surgery; 2010 Aug; 148(2):310-8. PubMed ID: 20466402
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells.
Agrawal V; Woo JH; Mauldin JP; Jo C; Stone EM; Georgiou G; Frankel AE
Anticancer Drugs; 2012 Jan; 23(1):51-64. PubMed ID: 21955999
[TBL] [Abstract][Full Text] [Related]
20. Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment.
Yu KM; Pang TP; Cutler M; Tian M; Huang L; Lau JY; Chung SF; Lo TW; Leung TY
Life Sci; 2021 Jan; 264():118674. PubMed ID: 33129876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
